Nuveen Real Estate Income Fund (JRS)

There is a reason why many investors tend to gravitate towards real estate: it has created more wealth than all other asset classes combined.

It also acts as a hedge against inflation: as the price of raw materials and labor goes up, new properties are more expensive to build. And that drives up the price of existing real estate.

As rental prices go up across the country in this inflationary environment, real estate investors have an opportunity to earn increased income.

Nuveen Real Estate Income Fund is a closed-end fund focusing on this particular sector. Its objective is “high current income and capital appreciation.”

The fund invests in income-producing common stocks, preferred stocks, convertible preferred stocks, and debt securities issued by companies in the real estate sector.

Notably, at least 75% of assets managed by JRS will be invested in investment-grade rated securities.

As of June 30, the fund’s top five industries were specialized REITs (21.3%), residential REITs (21.1%), office REITs (14.9%), retail REITs (14.5%), and industrial REITs (12.3%).

JRS pays quarterly distributions of 20.90 cents per share, which translates to an annual yield of 8.6%.

The fund has a net asset value of $10.12 per share and a share price of $9.72 — meaning it’s trading at roughly a 4% discount to its NAV.

Fundrise helps you invest in real estate without having to buy a house. Let their state-of-the-art technology and in-house experience open the door to new opportunities today.

Sign up

Tekla Healthcare Opportunities Fund (THQ)

Healthcare serves as a classic example of a defensive sector thanks to its lack of correlation with the ups and downs of the economy.

Income-seeking investors can use Tekla Healthcare Opportunities Fund to tap into the sector.

This closed-end fund invests across all healthcare sub-sectors and across a company’s capital structure. Its largest sector exposures were pharmaceuticals (29.0%), health care providers & services (24.7%), biotechnology (13.7%), health care equipment & supplies (13.6%), and medical devices and diagnostics (5.6%) at the end of June.

You can find many industry heavyweights in THQ’s portfolio, such as UnitedHealth Group, Johnson & Johnson, AbbVie, Pfizer, and Cigna.

Here’s the neat part: While most dividend-paying companies follow a quarterly distribution schedule, Tekla Healthcare Opportunities Fund pays shareholders on a monthly basis.

Right now, the fund has a monthly distribution rate of 11.25 cents per share, which comes out to an annual yield of 6.7%.

THQ currently trades at $20.09 per share — around a 7.5% discount to its NAV of $21.73 per share.

Pour your portfolio a glass of recession resistance

Fine wine is a sweet comfort in any situation — and now it can make your investment portfolio a little more comfortable, too.

Ownership in real assets like fine wine could be the diversification you need to protect your portfolio against the volatile effects of inflation and recession. High-net-worth investors have kept this secret to themselves for too long.

Now a platform called Vinovest helps everyday buyers invest in fine wines — no sommelier certification required.

Vinovest automatically selects the best wines for your portfolio based on your goals, and it tells you the best times to sell to get the best value for your wine.

About the Author

Jing Pan

Jing Pan

Investment Reporter

Jing is an investment reporter for MoneyWise. Prior to joining the team, he was a research analyst and editor at one of the leading financial publishing companies in North America. An avid advocate of investing for passive income, he wrote a monthly dividend stock newsletter for the better half of the past decade. Jing holds a Master’s Degree in Economics and an Honours Bachelor of Science Degree, both from the University of Toronto.

What to Read Next

Disclaimer

The content provided on MoneyWise is information to help users become financially literate. It is neither tax nor legal advice, is not intended to be relied upon as a forecast, research or investment advice, and is not a recommendation, offer or solicitation to buy or sell any securities or to adopt any investment strategy. Tax, investment and all other decisions should be made, as appropriate, only with guidance from a qualified professional. We make no representation or warranty of any kind, either express or implied, with respect to the data provided, the timeliness thereof, the results to be obtained by the use thereof or any other matter.